Individualized Survival and Treatment Response Predictions for Breast Cancers Using Phospho-EGFR,Phospho-ER,Phospho-HER2/neu,Phospho-IGF-IR/In,Phospho-MAPK,and Phospho-p70S6K Proteins

Abstract

The development and progression of breast cancer involves the activation of numerous protein kinases, and the change in phosphorylation is a hallmark of protein kinase activation. In this study, we identified a comprehensive profile to predict individual breast cancer patients’ survival and treatment responses using the Random Committee algorithm. The profile incorporated a subset of phosphorylated signal protein expressions and several selected clinical factors of breast cancer. The parameters of our profile were identified by supervised feature selection algorithms, Gain Ratio Attribute Evaluation and Relief. The results showed that the overall accuracy of survival prediction reached 92.3% for individual breast cancer patients with the use of the expression profiles of phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phospho-p70^S6K plus the selected clinical factors. The results also indicated that the overall accuracy of treatment response prediction was 92.6% with the use of the level of phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-MAPK, and phospho-p70^S6K plus the selected clinical information. The prediction system combines multiple signal protein activation profiles and relevant clinical information, and provides a unique guideline to aid individualized decision-making in the clinical management of breast cancer.

Keywords

Breast cancer Prediction Survival Treatment responses Active protein kinase

References

Murphy

, Millar

, Lee

C.S.

. Gene expression profiling in breast cancer: towards individualising patient management. Pathology 2005; 37: 271–7.

Rosen

J.M.

. Hormone receptor patterning plays a critical role in normal lobuloalveolar development and breast cancer progression. Breast Dis 2003; 18: 3–9.

Witten

I.H.

, Frank

. Data mining: Practical machine learning tools and techniques (2nd edition). San Francisco: Morgan Kaufmann 2005.

Warford

. Tissue microarrays: fast-tracking protein expression at the cellular level. Expert Rev Proteomics 2004; 1: 283–92.

Warford

, Howat

, McCafferty

. Expression profiling by high-throughput immunohistochemistry J Immunol Methods 2004; 290: 81–92.

Therasse

, Arbuck

S.G.

, Eisenhauer

E.A.

. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.

Kallakury

B.V.

, Sheehan

C.E.

, Ambros

R.A.

. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998; 16: 1302–9.

Ouban

, Muraca

, Yeatman

, Coppola

. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34: 803–8.

Allred

D.C.

, Clark

G.M.

, Elledge

. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200–6.

10.

American Joint Committee on Cancer Staging Manual, 5th ed. Philadelphia, PA: Lippincott-Raven 1997.

11.

Zaczek

, Brandt

, Bielawski

K.P.

. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005; 20: 1005–15.

12.

Atalay

, Cardoso

, Awada

, Piccart

M.J.

. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003; 14: 1346–63.

13.

Ross

J.S.

, Linette

G.P.

, Stec

. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003; 3: 573–85.

14.

Gee

J.M.

, Robertson

J.F.

, Ellis

I.O.

, Nicholson

R.I.

. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247–54.

15.

Mita

M.M.

, Mita

, Rowinsky

E.K.

. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003; 2(4 Suppl 1): S169–77.

16.

Bunone

, Briand

P.A.

, Miksicek

R.J.

, Picard

. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174–83.

17.

Hutcheson

I.R.

, Knowlden

J.M.

, Madden

T.A.

. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003; 81: 81–93.

18.

Lonning

P.E.

, Helle

S.I.

. IGF-1 and breast cancer. Novartis Found Symp 2004; 262: 205–12.

19.

Surmacz

, Bartucci

. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res 2004; 23: 385–94.

20.

Witten

I.H.

, Frank

. Data mining: Practical machine learning tools and techniques (2nd edition). San Francisco: Morgan Kaufmann 2005.

21.

Kohavi

. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of International Joint Conference on Artificial Intelligence (IJ-CAI) 1995; 1137–43.

22.

Hall

M.A.

, Holmes

. Benchmarking attribute selection techniques for discrete class data mining. IEEE Transactions on Knowledge and Data Engineering 2003; 15: 1437–47.

23.

Quinlan

J.R.

. Induction of decision tree. Machine Learning 1986; 1: 81–106.